Sacituzumab Govitecan

Antibody–drug conjugate

Approvedregulatory verdict

Evidence outlook

Approved: HR+/HER2- Metastatic Breast Cancer, Breast Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also in development:Non-Small Cell Lung Cancer · Phase 3Endometrial Cancer · Phase 3Urothelial Carcinoma · Phase 3

Also approved (8)
US
  • Locally Advanced or Metastatic Triple-Negative Breast Cancer First Line TRODELVY as a single agent is indicated for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1 or PD-L1 inhibitor based therapy. TRODELVY, in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, is indicated for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 [Combined Positive Score (CPS ≥ 10)] as determined by
  • Locally Advanced or Metastatic HR-positive, HER2-negative Breast Cancer TRODELVY is indicated for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.
Product first approved 2020FDA label
EU
  • Trodelvy as monotherapy for adults with unresectable or metastatic triple-negative breast cancer who have not received prior systemic therapy for metastatic disease and are not candidates for PD-(L)1 inhibitorsgilead.com
  • Monotherapy for unresectable or metastatic HR-positive, HER2-negative breast cancer after endocrine-based therapy and at least two further systemic therapiesgilead.com
  • Trodelvy: unresectable or metastatic triple-negative breast cancer after at least two prior therapies (initial authorisation)EMA
Product first approved 2021
JP
  • Treatment of hormone receptor-negative and human epidermal growth factor receptor 2 (HER2)-negative unresectable or recurrent breast cancer in patients who have previously been treated with chemotherapy
Product first approved 2024PMDA
CN
  • Unresectable locally advanced or metastatic triple-negative breast cancer after at least two prior systemic therapies (Everest Medicines)
Product first approved 2022biospace.com
CA
  • TRODELVY (sacituzumab govitecan) is indicated for: • the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior therapies, at least one of them for metastatic disease. • the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.
Product first approved 2021Health Canada

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (18)
Breast Cancer
NCT07178730 · Women's Cancer Study Group GmbH
2026-08-30 – 2033-03-31 · Breast Cancer, Triple-negative Breast Cancer
What this study did
NCT06081244 · Women's Cancer Study Group GmbH
2024-10-10 – 2029-09 · Triple Negative Breast Cancer
What this study did
NCT05552001 · UNICANCER
2023-10-05 – 2028-05-06 · Triple Negative Breast Cancer, Metastatic Breast Cancer
What this study did
Endometrial Cancer
HR+/HER2- Metastatic Breast Cancer
NCT04595565 · GBG Forschungs GmbH
2020-10-28 – 2029-03-30 · HER2-negative Breast Cancer, Triple Negative Breast Cancer
What this study did
NCT05840211 · Gilead Sciences
2023-05-08 – 2028-04 · Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer
What this study did
NCT04639986 · Gilead Sciences
2020-11-23 – 2026-12 · Metastatic Breast Cancer
What this study did
Non-Small Cell Lung Cancer
NCT06431633 · Fundación GECP
2025-02-04 – 2031-11-30 · Lung Diseases, Carcinoma, Non-Small-Cell Lung, Resectable Lung Non-Small Cell Carcinoma
What this study did
Urothelial Carcinoma
NCT06524544 · National Cancer Institute (NCI)
2025-12-02 – 2030-12-31 · Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
What this study did
Other / comorbidity
NCT06801834 · Gilead Sciences
2025-04-04 – 2029-10 · Extensive Stage Small Cell Lung Cancer (ES-SCLC)
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT06243393 · University Hospital Heidelberg
2024-04-19 – 2029-02-01 · Metastatic Colorectal Cancer
What this study did
Phase 2 (76)
Breast Cancer
NCT07271992 · First Hospital of China Medical University
2025-12-15 – 2031-12-14 · TNBC, Triple Negative Breast Cancer
What this study did
NCT05332561 · German Cancer Research Center
2023-06-29 – 2030-12 · Early-stage Breast Cancer
What this study did
NCT07947823 · Massachusetts General Hospital
2027-04-21 – 2030-09-01 · Breast Cancer, HR Positive/HER-2 Negative Breast Cancer, High-risk Breast Cancer, Early-Stage Breast Cancer
What this study did
NCT04230109 · Massachusetts General Hospital
2020-07-14 – 2029-10 · Invasive Breast Cancer, Triple Negative Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, HER2-negative Breast Cancer
What this study did
NCT07151586 · UNICANCER
2026-09 – 2029-10 · Triple Negative Breast Neoplasms, Neoplasm Metastasis, HER 2 Low-expressing Breast Cancer
What this study did
NCT04468061 · Dana-Farber Cancer Institute
2020-07-20 – 2029-04-01 · Breast Cancer, Triple Negative Breast Cancer, PD-L1 Negative
What this study did
NCT07134556 · MedSIR
2026-04 – 2028-12-28 · Triple Negative Breast Cancer, PDL-1 Positive
What this study did
NCT07299409 · Nathalie Levasseur
2026-01-20 – 2028-03 · Advanced Triple Negative Breast Cancer, Breast Cancer Metastatic, Breast Cancer
What this study did
NCT06616987 · Yeon Hee Park
2025-07-03 – 2027-12-31 · Breast Cancer Metastatic
What this study did
NCT04434040 · Dana-Farber Cancer Institute
2020-07-02 – 2027-12-30 · Breast Cancer, Triple Negative Breast Cancer, Residual Cancer, Circulating Tumor DNA
What this study did
NCT04454437 · Gilead Sciences
2020-10-23 – 2027-12 · Metastatic Triple-negative Breast Cancer
What this study did
NCT06100874 · Adrienne G. Waks
2023-11-20 – 2027-11-30 · Her 2 Positive Breast Cancer, Breast Cancer Female, Breast Cancer Metastatic
What this study did
NCT06878625 · Tianjin Medical University Cancer Institute and Hospital
2024-12-06 – 2027-06-30 · Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast Cancer
What this study did
NCT03971409 · Laura Huppert, MD, BA
2019-07-08 – 2027-01-31 · Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Triple-Negative Breast Carcinoma, Unresectable Breast Carcinoma
What this study did
NCT07359404 · YING FAN
2024-04-01 – 2026-12-31 · Advanced Breast Cancer
What this study did
NCT05675579 · M.D. Anderson Cancer Center
2023-05-23 – 2026-12-31 · Breast Cancer
What this study did
NCT03606967 · National Cancer Institute (NCI)
2021-04-13 – 2026-12-30 · Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma
What this study did
NCT05520723 · MedSIR
2023-02-06 – 2025-11-05 · Triple Negative Breast Cancer, Breast Cancer, Advanced HR+/HER2- Breast Cancer
What this study did
NCT04958785 · Gilead Sciences
2021-12-14 – 2024-10-08 · Triple-Negative Breast Cancer
What this study did
NCT05113966 · G1 Therapeutics, Inc.
2021-12-08 – 2024-06-13 · Triple Negative Breast Cancer
What this study did
NCT05008510 · Veru Inc.
2021-12-30 – 2023-06-30 · Metastatic Triple Negative Breast Cancer
What this study did
NCT02161679 · Gilead Sciences
2016-08 – 2016-08 · Triple-negative Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT04986579 · Dana-Farber Cancer Institute
2021-10-07 – 2030-06-01 · Metastatic Breast Cancer, Chemotherapy-induced Alopecia
What this study did
NCT07825753 · Fudan University
2026-09-10 – 2030-02-01 · Advanced or Metastatic Pancreatic Adenocarcinoma, Advanced or Metastatic Breast Cancer (BC)
What this study did
NCT07471776 · Fudan University
2026-03-11 – 2029-03-11 · Metastatic Breast Cancer ( HER2 Negative)
What this study did
NCT06665178 · British Columbia Cancer Agency
2025-03-31 – 2028-12-01 · Breast Cancer
What this study did
NCT07368543 · Fudan University
2026-01-16 – 2028-12-01 · Metastatic Breast Cancer
What this study did
NCT04647916 · SWOG Cancer Research Network
2021-06-08 – 2028-12 · Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8
What this study did
NCT06263543 · Reshma L. Mahtani, D.O.
2024-06-17 – 2028-12 · Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Low Breast Cancer
What this study did
NCT05601440 · Canadian Cancer Trials Group
2023-06-13 – 2028-06-30 · Breast Cancer
What this study did
NCT07367178 · MedSIR
2026-07 – 2028-01 · Breast Cancer, Advanced HR+/HER2- Breast Cancer, Advanced Triple-Negative Breast Cancer
What this study did
NCT06462079 · Guangzhou Medical University
2024-06-15 – 2027-07-15 · Brain Metastasis
What this study did
NCT04448886 · Ana C Garrido-Castro, MD
2020-09-23 – 2027-06-01 · Invasive Breast Cancer, Metastatic Breast Cancer, HR-Positive Breast Cancer, HER2-negative Breast Cancer
What this study did
NCT06409390 · H. Lee Moffitt Cancer Center and Research Institute
2024-08-14 – 2027-04 · Metastatic Breast Cancer
What this study did
NCT06236269 · SOLTI Breast Cancer Research Group
2024-03-15 – 2027-02-20 · Breast Cancer Stage IV
What this study did
Non-Small Cell Lung Cancer
NCT06055465 · Chinese University of Hong Kong
2024-02-28 – 2029-12-30 · Lung Cancer
What this study did
NCT07393555 · SWOG Cancer Research Network
2026-09-22 – 2029-11 · Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
What this study did
NCT05633667 · Gilead Sciences
2023-03-16 – 2029-09 · Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer
What this study did
NCT06667167 · Nir Peled
2024-12-24 – 2028-11-01 · NSCLC (non-small Cell Lung Cancer)
What this study did
NCT07438600 · Tianjin Medical University Cancer Institute and Hospital
2026-02-24 – 2028-02-28 · NSCLC (Non-small Cell Lung Cancer)
What this study did
NCT06401824 · Maastricht University Medical Center
2025-04-24 – 2027-04-01 · NSCLC Stage IV, Brain Metastases, Adult
What this study did
NCT05186974 · Gilead Sciences
2022-05-30 – 2027-03 · Non-small Cell Lung Cancer
What this study did
Urothelial Carcinoma
NCT03547973 · Gilead Sciences
2018-08-13 – 2030-04 · Metastatic Urothelial Cancer
What this study did
NCT06528483 · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
2024-12-02 – 2029-12-31 · Bladder Cancer, Bladder Urothelial Carcinoma, Bladder Neoplasm, Muscle-Invasive Bladder Carcinoma
What this study did
NCT05535218 · Claudia Guerrieri
2023-09-20 – 2027-02 · Muscle-invasive Urothelial Carcinoma of the Bladder
What this study did
NCT05327530 · EMD Serono Research & Development Institute, Inc.
2022-08-17 – 2027-01-22 · Locally Advanced or Metastatic Urothelial Carcinoma
What this study did
NCT06682728 · University of California, Irvine
2024-11-15 – 2026-12-01 · Urothelial Carcinoma, Muscle-invasive Bladder Cancer
What this study did
NCT05226117 · IRCCS San Raffaele
2022-03-23 – 2025-09-24 · Urothelial Carcinoma
What this study did
Other / comorbidity
NCT07492914 · West China Hospital
2026-05-11 – 2031-03-31 · Resectable Head and Neck Squamous Cell Carcinoma
What this study did
NCT06133517 · Fundación para el Progreso de la Oncología en Cantabria
2025-01-20 – 2030-12 · Urothelial Bladder Carcinoma
What this study did
Phase 1/2 (24)
Breast Cancer
NCT06963905 · Yale University
2025-12-29 – 2030-12 · Metastatic Triple-negative Breast Cancer
What this study did
NCT07011654 · M.D. Anderson Cancer Center
2025-09-19 – 2030-07-01 · Metastatic Triple-Negative Breast Cancer
What this study did
NCT06926920 · Gilead Sciences
2025-04-30 – 2028-06 · Triple Negative Breast Cancer
What this study did
NCT06238921 · H. Lee Moffitt Cancer Center and Research Institute
2024-12-19 – 2027-02 · Breast Cancer, Triple Negative Breast Cancer
What this study did
NCT04927884 · ImmunityBio, Inc.
2021-09-08 – 2022-12-12 · Advanced Triple Negative Breast Cancer
What this study did
Endometrial Cancer
NCT06040970 · Icahn School of Medicine at Mount Sinai
2024-10-28 – 2032-07-01 · Ovarian Cancer, Malignant Neoplasm of Uterus
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT03424005 · Hoffmann-La Roche
2018-03-30 – 2030-09-30 · Metastatic Breast Cancer
What this study did
NCT05867251 · Avenzo Therapeutics, Inc.
2023-08-30 – 2030-01-31 · Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CCNE1 Amplification, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Endometrial Cancer, TNBC - Triple-Negative Breast Cancer
What this study did
NCT04039230 · Massachusetts General Hospital
2019-10-09 – 2029-01 · Breast Cancer
What this study did
NCT06827613 · Marengo Therapeutics, Inc.
2025-03-24 – 2028-01 · Triple Negative Locally Advanced Non-resectable Breast Cancer, HR+, HER2-, Advanced Breast Cancer
What this study did
NCT06612203 · MedSIR
2025-01-17 – 2027-10 · Advanced Breast Cancer
What this study did
NCT06462092 · Guangzhou Medical University
2026-01-01 – 2027-06-15 · Leptomeningeal Metastases
What this study did
NCT05101096 · Gilead Sciences
2021-10-20 – 2027-05 · Advanced Solid Tumor, Metastatic Triple-Negative Breast Cancer, HR+/HER2- Metastatic Breast Cancer, Metastatic Urothelial Cancer
What this study did
NCT06328387 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2024-01-29 – 2026-03-01 · Advanced Breast Cancer, Metastatic Breast Cancer
What this study did
Non-Small Cell Lung Cancer
NCT03337698 · Hoffmann-La Roche
2017-12-27 – 2025-11-25 · Carcinoma, Non-Small-Cell Lung
What this study did
Urothelial Carcinoma
NCT04724018 · Dana-Farber Cancer Institute
2021-05-20 – 2028-05-01 · Urothelial Cancer, Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter, Bladder Cancer
What this study did
NCT04863885 · H. Lee Moffitt Cancer Center and Research Institute
2021-04-30 – 2027-10 · Metastatic Urothelial Carcinoma
What this study did
NCT03869190 · Hoffmann-La Roche
2019-06-01 – 2025-12-22 · Urothelial Carcinoma, Bladder Cancer
What this study did
NCT03992131 · pharmaand GmbH
2019-06-28 – 2022-04-22 · Ovarian Cancer, Triple-negative Breast Cancer, Urothelial Carcinoma, Solid Tumor
What this study did
Other / comorbidity
NCT04826341 · National Cancer Institute (NCI)
2021-09-20 – 2026-07-01 · HRD Cancer, SCLC, Advanced Solid Tumors
What this study did
NCT07328490 · National Cancer Institute (NCI)
2026-04-25 – 2026-04-25 · Extensive-Stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma, Small Cell Carcinoma
What this study did
NCT06123468 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2024-04-17 – 2026-01-07 · Esophagogastric Adenocarcinoma
What this study did
NCT04143711 · Dragonfly Therapeutics
2019-11-11 – 2025-12-05 · Solid Tumor, Adult
What this study did
Phase 1 (10)
HR+/HER2- Metastatic Breast Cancer
NCT07163481 · Hunan Cancer Hospital
2025-10 – 2026-12 · Stage IV (Metastatic) Breast Cancer
What this study did
NCT05143229 · University of Kansas Medical Center
2022-03-28 – 2026-12 · Breast Cancer
What this study did
Urothelial Carcinoma
NCT05833867 · Shilpa Gupta, MD
2024-04-01 – 2027-10 · Localized Muscle Invasive Bladder Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma
What this study did
Other / comorbidity
NCT06167317 · Gilead Sciences
2024-01-09 – 2028-09 · Advanced Solid Tumors
What this study did
NCT07674615 · Shanghai Gynecologic Oncology Group
2026-09-02 – 2027-06-30 · Epithelial Ovarian Cancer, Fallopian Tube Cancers, Primary, Primary Peritoneal Carcinoma
What this study did
NCT06065371 · Henry Ford Health System
2024-11-20 – 2027-05 · Gastrointestinal Cancer
What this study did
NCT04794699 · IDEAYA Biosciences
2021-04-14 – 2027-02-04 · Solid Tumor
What this study did
NCT04617522 · Gilead Sciences
2021-04-06 – 2026-12 · Advanced or Metastatic Solid Tumor, Liver Failure
What this study did
NCT03995706 · The University of Texas Health Science Center at San Antonio
2019-07-17 – 2024-03-20 · Glioblastoma
What this study did
Phase 4 (1)
Other / comorbidity
NCT04319198 · Gilead Sciences
2020-08-04 – 2024-10-18 · Metastatic Solid Tumors
What this study did
Early phase / not applicable (1)
Breast Cancer
NCT07046455 · Peking University Cancer Hospital & Institute
2025-03-01 – 2027-09-01 · TNBC - Triple-Negative Breast Cancer
What this study did
Used as active comparator (4)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (3)
Breast Cancer
NCT07533123 · Jiangsu Alphamab Biopharmaceuticals Co., Ltd
2026-03-17 – 2030-03-17 · Triple Negative Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07461454 · MediLink Therapeutics (Suzhou) Co., Ltd.
2026-03-17 – 2028-06-30 · Locally Advanced or Metastatic Breast Cancer
What this study did
Urothelial Carcinoma
NCT04579224 · National Cancer Institute (NCI)
2021-06-28 – 2027-10-29 · Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma, Refractory Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8
What this study did
Phase 2 (1)
HR+/HER2- Metastatic Breast Cancer
NCT06102824 · Guangdong Provincial People's Hospital
2024-10-01 – 2028-06-30 · HER2-negative Breast Cancer, Advanced Breast Cancer
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (1)
Other / comorbidity
NCT07778368 · Shanghai East Hospital
2026-09-01 – 2029-08-31 · Oral Squamous Cell Carcinoma (OSCC)
What this study did

Competitive landscape

7 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Breast Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Sacituzumab Govitecan: this drugApprovedAntibody–drug conjugateTROP2Partial signal
NCT03901339: Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Up to 42.8 months): Sacituzumab Govitecan 5.5 months (95% CI 4.2 to 6.9) vs Treatment of Physician's Choice (TPC) 4 months (95% CI 3 to 4.4)
NCT02574455: Progression-Free Survival (PFS) by Independent Review Committee (IRC) Assessment in Brain Metastasis Negative (BM-ve) Population (From randomization until objective tumor progression or death (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months)): Sacituzumab Govitecan 5.6 months (95% CI 4.3 to 6.3) vs Treatment of Physician's Choice (TPC) 1.7 months (95% CI 1.5 to 2.6)
Abemaciclib (Verzenio)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02107703: Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Abemaciclib + Fulvestrant 16.4 Months (95% CI 14.4 to 19.3) vs Placebo + Fulvestrant 9.3 Months (95% CI 7.4 to 11.4)
NCT02102490: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) (From Date of First Dose until Disease Progression or Death Due to Any Cause (Up To 14 Months)): Abemaciclib 19.7% (95% CI 13.3 to 27.5)
Alpelisib (BYL719)ApprovedSmall moleculePI3K-alphaReliable signal
NCT02437318: Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort (Once approximately 243 PFS events in the PIK3CA mutant cohort had been observed, up to 33.3 months): PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant 11 Months (95% CI 7.49 to 14.52) vs PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant 5.7 Months (95% CI 3.65 to 7.36)
Camizestrant (Etcamah)ApprovedSmall moleculeEstrogen receptorReliable signal
NCT04964934: SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001
NCT04588298: Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis) (Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])): AZD9833 75 mg (Stage 1 + 2) -62.7% (95% CI -67.46--57.93) vs AZD9833 150 mg (Stage 1 + 2) -62.8% (95% CI -67.13--58.43) vs AZD9833 300 mg (Stage 2) -67.1% (95% CI -74.49--59.74) vs AZD9833 75 mg (Stage 3) -66.9% (95% CI -72.34--61.46) vs AZD9833 150 mg (Stage 3) -65.0% (95% CI -70.27--59.81)
CapivasertibApprovedSmall moleculeAKT (inhibitor)Reliable signal
NCT04305496: Progression Free Survival: Overall Population (Months) in the Global Cohort (Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.): Capivasertib + Fulvestrant (Global + China Cohort) 7.2 Months (95% CI 5.5 to 7.4) vs Placebo + Fulvestrant (Global + China Cohort) 3.6 Months (95% CI 2.8 to 3.7)
NCT01625286: Progression-free survival, Part B (randomized vs placebo + paclitaxel): median 10.9 months (95% CI 8.3 to 12.4) with capivasertib vs 8.4 months (95% CI 8.2 to 10.8) with placebo; HR 0.80 (95% CI 0.60 to 1.06), p=0.308 (CT.gov posted results). missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT05104866: Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months): Dato-DXd 6.9 Months (95% CI 5.7 to 7.4) vs Investigator's Choice of Chemotherapy (ICC) 4.9 Months (95% CI 4.2 to 5.5)
ElacestrantApprovedSmall moleculeEstrogen receptorPartial signal
NCT03778931: Progression-free Survival in ESR1-mut Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)): Elacestrant 3.78 months (95% CI 2.17 to 7.26) vs Standard of Care (SoC) 1.87 months (95% CI 1.87 to 2.14)
EpirubicinApprovedSmall moleculeTopoisomerase II / DNAPartial signal
NCT00309569: Overall survival (primary endpoint), preoperative vs postoperative chemo timing: HR 0.800 (95% CI 0.563-1.136), P=0.213 — no significant difference. (Secondary endpoint recurrence-free survival: HR 0.7, 95% CI 0.515-0.955, P=0.024, favoring postoperative chemo.) missed
Eribulin MesylateApprovedSmall moleculeTubulin / microtubulesPartial signal
NCT02225470: Progression-Free Survival, eribulin vs vinorelbine (independent tumor assessment): HR 0.80 (95% CI 0.65-0.98, P=0.036) in favor of eribulin; median PFS 2.8 months in both arms
NCT00337103: Co-primary endpoints, eribulin (n=554) vs capecitabine (n=548): overall survival median 15.9 vs 14.5 months, HR 0.88 (95% CI 0.77 to 1.00), P = .056; progression-free survival median 4.1 vs 4.2 months, HR 1.08 (95% CI 0.93 to 1.25), P = .30 (Kaufman et al., J Clin Oncol 2015). missed
EverolimusApprovedSmall moleculemTOR kinase, mTOR (mTORC1) (inhibitor)Partial signal
NCT02511639: Median progression-free survival: 9.9 months (everolimus + aromatase inhibitor) vs 7.2 months (aromatase inhibitor alone); HR 0.764 (95% CI 0.501-1.164)
NCT00863655: Progression-free Survival (PFS) Based on Local Radiology Review of Tumor Assessments. (date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to about 19 months): Everolimus + Exemestane 6.93 months (95% CI 6.44 to 8.05) vs Placebo + Exemestane 2.83 months (95% CI 2.76 to 4.14)
ExemestaneApprovedSmall moleculeAromataseReliable signal
NCT00038467: Disease-Free Survival (DFS) at Month 36 Post-Randomization: Main Study (Baseline up to Month 36): Exemestane 0.9 probability of DFS (95% CI 0.89 to 0.92) vs Tamoxifen 0.86 probability of DFS (95% CI 0.85 to 0.88)
NCT00066690: 5-year disease-free survival: 89.0% exemestane plus ovarian function suppression vs 84.7% tamoxifen alone; HR 0.68 (95% CI 0.53–0.86).
Fulvestrant (Faslodex)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT01602380: Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Fulvestrant 500 mg 16.6 Months (95% CI 13.83 to 20.99) vs Anastrozole 1 mg 13.8 Months (95% CI 11.99 to 16.59)
NCT00099437: Progression-free survival: fulvestrant 500 mg (n=362) vs 250 mg (n=374), HR 0.80 (95% CI 0.68 to 0.94), P = .006; CT.gov median time to progression 6.5 vs 5.5 months (Di Leo et al., J Clin Oncol 2010).
Gedatolisib (Revtorpyk)ApprovedSmall moleculePI3K (class I isoforms) and mTORC1/mTORC2Partial signal
NCT05501886: VIKTORIA-1 (NCT05501886), PIK3CA wild-type cohort, primary endpoint PFS: gedatolisib+fulvestrant+palbociclib (triplet) median PFS 9.3 months vs fulvestrant alone 2.0 months, HR 0.24 (95% CI 0.17-0.35), p<0.0001; gedatolisib+fulvestrant (doublet) median PFS 7.4 months, HR 0.33 (95% CI 0.24-0.48), p<0.0001.
Imlunestrant (Inluriyo)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT04975308: Investigator-assessed PFS. ESR1-mutated population: imlunestrant 5.49 vs 3.84 months with standard endocrine therapy, HR 0.617 (95% CI 0.464 to 0.821), p=0.0008. All patients: 5.55 vs 5.52 months, HR 0.867 (95% CI 0.724 to 1.039), p=0.1158 (not significant). Imlunestrant plus abemaciclib vs imlunestrant: 9.36 vs 5.49 months, HR 0.569 (95% CI 0.441 to 0.733), p<0.0001
Inavolisib (Itovebi)ApprovedSmall moleculePI3K-alphaReliable signal
NCT04191499: Progression-Free Survival (PFS) (Up to 3.7 years): Inavo+Palbo+Fulv 15 months (95% CI 11.3 to 20.5) vs Pbo+Palbo+Fulv 7.3 months (95% CI 5.6 to 9.3)
IxabepiloneApprovedSmall moleculeMicrotubules (tubulin)Partial signalFeatured results are non-efficacy only in this race
Margetuximab (Margenza)ApprovedMonoclonal antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00785291: Progression Free Survival (Time from randomization to progression or death due to any cause, whichever occurs first (up to 5 years)): Arm B (Nab-paclitaxel) 9.3 months (95% CI 8.15 to 10.45) vs Arm A (Paclitaxel) 10.97 months (95% CI 9.79 to 12.42) vs Arm C (Ixabepilone) 7.36 months (95% CI 6.21 to 8.18) missed
NeratinibApprovedSmall moleculeEGFR/HER2Reliable signal
NCT00878709: Invasive Disease-free Survival (iDFS) in Neratinib Arm Compared to Placebo Arm at Year 2 (From randomization until time of event up to 2 years): Neratinib 4.7 percentage of participants with events vs Placebo 7.5 percentage of participants with events
NCT01808573: Centrally Assessed Progression Free Survival (From randomization date to recurrence, progression or death, assessed up to 38 months. The result is based on primary analysis data cut.): Neratinib Plus Capecitabine 8.8 months (95% CI 7.8 to 9.8) vs Lapatinib Plus Capecitabine 6.6 months (95% CI 5.9 to 7.4)
OlaparibApprovedSmall moleculePARPPartial signal
NCT02000622: Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) (Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.): Olaparib 300 mg bd 7 Months (95% CI 5.7 to 8.3) vs Chemotherapy 4.2 Months (95% CI 2.8 to 4.3)
NCT03286842: Progression-free Survival (PFS) in Real-world Setting in Germline BRCA Mutated Participants (At every visit until the earliest of disease progression, death or end of study (up to 3 years)): Olaparib gBRCAm Cohort 8.18 months (95% CI 6.97 to 9.17)
Palbociclib (Ibrance)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02297438: Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Palbociclib + Letrozole 21.5 Months (95% CI 16.6 to 24.9) vs Placebo + Letrozole 13.9 Months (95% CI 13.7 to 16.6)
NCT01740427: Progression-Free Survival (PFS) as Assessed by the Investigator (From randomization date to date of first documentation of progression or death (up to approximately 2.5 years)): Palbociclib Plus Letrozole 24.8 Months vs Placebo Plus Letrozole 14.5 Months (95% CI 12.9 to 17.1)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PertuzumabApprovedMonoclonal antibodyHER2/neu Receptor AntagonistPartial signal
NCT01358877: IDFS events, pertuzumab + trastuzumab + chemotherapy vs placebo + trastuzumab + chemotherapy: 7.1% vs 8.7%, hazard ratio 0.81 (95% CI 0.66 to 1.00), p=0.0446 (log-rank); 3-year IDFS event-free rate 94.06% vs 93.24% (CT.gov posted results, data cut-off 19 December 2016).
NCT00567190: IRF-assessed progression-free survival, pertuzumab + trastuzumab + docetaxel vs placebo + trastuzumab + docetaxel: median 18.5 vs 12.4 months, hazard ratio 0.62 (95% CI 0.51 to 0.75), p<0.0001 (stratified log-rank; CT.gov posted results).
RibociclibApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02422615: Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Ribociclib + Fulvestrant 20.5 Months (95% CI 18.5 to 23.5) vs Placebo + Fulvestrant 12.8 Months (95% CI 10.9 to 16.3)
NCT02278120: Progression Free Survival (PFS) by Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 29 months): Ribociclib + NSAI/Tamoxifen + Goserelin 23.8 Months vs Placebo + NSAI/Tamoxifen+ Goserelin 13 Months (95% CI 11 to 16.4)
TalazoparibApprovedSmall moleculePARPPartial signal
NCT01945775: Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment (Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months)): Talazoparib 8.6 months (95% CI 7.2 to 9.3) vs Physician's Choice Treatment 5.6 months (95% CI 4.2 to 6.7)
Tamoxifen (Soltamox)ApprovedSmall moleculeEstrogen receptornot yet graded
NCT00066690: Disease-free Survival (5-year estimates, reported at a median follow-up of 67 months.): T+OFS 86.6% (95% CI 84.2 to 88.7) | E+OFS 89% (95% CI 86.8 to 90.9) vs Tamoxifen 84.7% (95% CI 82.2 to 86.9) phase 3 result · pivotal pending
NCT00309478: At median 60-month follow-up: relapse rate 17.2% (goserelin+tamoxifen) vs 20.8% (CMF), relapse-free survival difference P=.037; local recurrence 4.7% vs 8.0%, P=.015; overall survival difference only a trend, P=.195. phase 3 result · pivotal pending
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Partial signal
NCT04494425: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population (Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)): T-DXd 13.2 months (95% CI 11.4 to 15.2) | Chemotherapy 8.1 months (95% CI 7 to 9)
NCT03734029: Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer (From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years): Trastuzumab Deruxtecan (T-DXd) 10.1 months (95% CI 9.5 to 11.5) | Physician's Choice 5.4 months (95% CI 4.4 to 7.1)
Trastuzumab EmtansineApprovedAntibody–drug conjugateHER2 (ERBB2)Partial signalFeatured results are non-efficacy only in this race
TucatinibApprovedSmall moleculeHER2Reliable signal
NCT05132582: HER2CLIMB-05 (NCT05132582), primary endpoint PFS: median 24.9 months with tucatinib vs 16.3 months with placebo; HR 0.641 (95% CI 0.514-0.799); P<.0001.
NCT03975647: Progression-Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 Based on Investigator Assessment (From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to 43 months)): Tucatinib+ Ado-trastuzumab Emtansine 9.5 Months (95% CI 7.4 to 10.9) vs Placebo+ Ado-trastuzumab Emtansine 7.4 Months (95% CI 5.6 to 8.1)
Vepdegestrant (Veppanu)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT05654623: PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025).
NCT04072952: Clinical benefit rate 38% (total n=71), the trial's primary endpoint (VERITAC expansion); CBR 51.2% in ESR1-mutant patients (n=41)
BEBT-209Phase 3Small moleculeCDK4 (selective)not yet gradedNo reviewed efficacy summary in this indication
CPO301Phase 3Antibody–drug conjugateEGFRnot yet gradedNo reviewed efficacy summary in this indication
Patritumab DeruxtecanPhase 3Antibody–drug conjugateHER3Weak signalNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2Partial signal
NCT05347134: OptiTROP-Breast01 (NCT05347134), primary endpoint median PFS: sac-TMT 6.7 months vs chemotherapy 2.5 months; HR 0.32 (95% CI 0.24-0.44); p<0.00001
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
(Z)-EndoxifenPhase 2Small moleculeEstrogen receptor (antagonist)Partial signal
NCT03931928: Primary endpoint (proportion of patients with steady-state (Z)-endoxifen plasma concentration >32 nmol/L after 6 weeks): higher proportion achieved target in both (Z)-endoxifen supplementation arms (3mg and 1.5mg) than in the control/placebo arm, P<0.0001.
JS207Phase 2Multispecific antibodyPD-1 + VEGFAnot yet gradedNo reviewed efficacy summary in this indication
TersolisibPhase 2Small moleculePI3K-alpha (mutant-selective, allosteric)not yet gradedNo reviewed efficacy summary in this indication
ECI830Phase 1/2Small moleculeCDK2not yet gradedNo reviewed efficacy summary in this indication
GVV858Phase 1/2—CDK2not yet gradedNo reviewed efficacy summary in this indication
HRS-2189Phase 1/2UndisclosedKAT6A / KAT6Bnot yet gradedNo reviewed efficacy summary in this indication
HRS-6208Phase 1/2UndisclosedCDK7not yet gradedNo reviewed efficacy summary in this indication
TegtociclibPhase 1/2Small moleculeCDK2not yet gradedNo reviewed efficacy summary in this indication
IEV407Phase 1——not yet gradedNo reviewed efficacy summary in this indication
JNJ-101684362Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
RAE346
—(overall)
Small moleculePI3Kα (mutant-selective)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(90 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Sacituzumab Govitecan to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (16)
November 2026 (1)
Phase 2Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2026-11 · NCT06329869 · CT.gov ↗
What to watch
December 2026 (15)
Phase 1HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2026-12 · NCT07163481 · CT.gov ↗
What to watch
Phase 1Gastrointestinal CancerRecruiting
Est. primary completion 2026-12 · NCT06065371 · CT.gov ↗
What to watch
Phase 1Advanced or Metastatic Solid Tumor, Liver FailureRecruiting
Est. primary completion 2026-12 · NCT04617522 · CT.gov ↗
What to watch
Phase 1Urothelial CarcinomaRecruiting
Est. primary completion 2026-12 · NCT05833867 · CT.gov ↗
What to watch
Phase 2Endometrial CarcinomaActive not recruiting
Est. primary completion 2026-12 · NCT04251416 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12 · NCT04639986 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaRecruiting
Est. primary completion 2026-12-01 · NCT06682728 · CT.gov ↗
What to watch
Phase 2Cervical CancerRecruiting
Est. primary completion 2026-12-01 · NCT05838521 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2026-12-30 · NCT04434040 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2026-12-30 · NCT03606967 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaNot yet recruiting
Est. primary completion 2026-12-31 · NCT06528483 · CT.gov ↗
What to watch
Phase 2Solid Tumor, Precision MedicineRecruiting
Est. primary completion 2026-12-31 · NCT06739395 · CT.gov ↗
What to watch
Phase 2Breast CancerEnrolling by invitation
Est. primary completion 2026-12-31 · NCT07359404 · CT.gov ↗
What to watch
Phase 2Resectable Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT07492914 · CT.gov ↗
What to watch
Phase 2Breast CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT05675579 · CT.gov ↗
What to watch
2027 (36)
January 2027 (7)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-01 · NCT06827613 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-01 · NCT04039230 · CT.gov ↗
What to watch
Phase 1Solid TumorActive not recruiting
Est. primary completion 2027-01-07 · NCT04794699 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-01-12 · NCT05609968 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-01-15 · NCT06462092 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-01-15 · NCT06462079 · CT.gov ↗
What to watch
Phase 2Breast CancerActive not recruiting
Est. primary completion 2027-01-31 · NCT03971409 · CT.gov ↗
What to watch
February 2027 (6)
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-02 · NCT06612203 · CT.gov ↗
What to watch
Phase 1/2Breast CancerRecruiting
Est. primary completion 2027-02 · NCT06238921 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaActive not recruiting
Est. primary completion 2027-02 · NCT05535218 · CT.gov ↗
What to watch
Phase 3Breast CancerActive not recruiting
Est. primary completion 2027-02 · NCT05382286 · CT.gov ↗
What to watch
Phase 1/2Urothelial CarcinomaRecruiting
Est. primary completion 2027-02-01 · NCT04724018 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-02-28 · NCT07438600 · CT.gov ↗
What to watch
March 2027 (3)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-03 · NCT05186974 · CT.gov ↗
What to watch
Early phase / not applicableBreast CancerRecruiting
Est. primary completion 2027-03-01 · NCT07046455 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-03-30 · NCT04595565 · CT.gov ↗
What to watch
April 2027 (2)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-04 · NCT06409390 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-04-01 · NCT04468061 · CT.gov ↗
What to watch
May 2027 (3)
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-05 · NCT05101096 · CT.gov ↗
What to watch
Phase 2Thymoma, Thymic CarcinomaRecruiting
Est. primary completion 2027-05 · NCT06248515 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-05-01 · NCT06665178 · CT.gov ↗
What to watch
June 2027 (7)
Phase 2Triple Negative Breast NeoplasmsNot yet recruiting
Est. primary completion 2027-06 · NCT07040644 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-06 · NCT07367178 · CT.gov ↗
What to watch
Phase 3Breast CancerRecruiting
Est. primary completion 2027-06 · NCT05633654 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-06-01 · NCT07368543 · CT.gov ↗
What to watch
Phase 1Epithelial Ovarian Cancer, Fallopian Tube Cancers, Primary, Primary Peritoneal CarcinomaRecruiting
Est. primary completion 2027-06-30 · NCT07674615 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-06-30 · NCT06878625 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-06-30 · NCT06616987 · CT.gov ↗
What to watch
August 2027 (2)
Phase 2Breast CancerRecruiting
Est. primary completion 2027-08 · NCT07299409 · CT.gov ↗
What to watch
Phase 2Recurrent GlioblastomaRecruiting
Est. primary completion 2027-08 · NCT04559230 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-09-01 · NCT07825753 · CT.gov ↗
What to watch
November 2027 (2)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-11-01 · NCT06667167 · CT.gov ↗
What to watch
Phase 2Small Cell Carcinoma of the Bladder, Small Cell Carcinoma of the Urinary Tract, Squamous Cell Carcinoma of the Bladder …Recruiting
Est. primary completion 2027-11-01 · NCT06161532 · CT.gov ↗
What to watch
December 2027 (3)
Phase 2Differentiated Thyroid Cancer, Anaplastic Thyroid CancerRecruiting
Est. primary completion 2027-12 · NCT06235216 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT04647916 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT05601440 · CT.gov ↗
What to watch
2028 (19)
January 2028 (2)
Phase 2Squamous Cell Carcinoma of Head and Neck, Sinus Cancer, Nasal Cavity Cancer, Oral Cavity Cancer, Oropharynx Cancer, Hypopharynx Cancer …Recruiting
Est. primary completion 2028-01-02 · NCT07063212 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-01-31 · NCT05867251 · CT.gov ↗
What to watch
March 2028 (2)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-03-11 · NCT07471776 · CT.gov ↗
What to watch
Phase 2Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid NeoplasmRecruiting
Est. primary completion 2028-03-31 · NCT06311214 · CT.gov ↗
What to watch
April 2028 (1)
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2028-04 · NCT05840211 · CT.gov ↗
What to watch
May 2028 (1)
Phase 2Triple Negative Breast NeoplasmsNot yet recruiting
Est. primary completion 2028-05-31 · NCT07788222 · CT.gov ↗
What to watch
June 2028 (3)
Phase 1/2Breast CancerRecruiting
Est. primary completion 2028-06 · NCT06926920 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-06 · NCT06263543 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-06-01 · NCT04986579 · CT.gov ↗
What to watch
July 2028 (3)
Phase 3Breast CancerActive not recruiting
Est. primary completion 2028-07 · NCT05382299 · CT.gov ↗
What to watch
Phase 1/2Breast CancerRecruiting
Est. primary completion 2028-07-01 · NCT07011654 · CT.gov ↗
What to watch
Phase 2Gland, Salivary Gland CancersActive not recruiting
Est. primary completion 2028-07-31 · NCT05884320 · CT.gov ↗
What to watch
August 2028 (2)
Phase 2Metastatic HER2-Negative Breast Carcinoma, Metastatic Triple-Negative Breast CarcinomaRecruiting
Est. primary completion 2028-08-01 · NCT05770531 · CT.gov ↗
What to watch
Phase 2/3Metastatic Colorectal CancerRecruiting
Est. primary completion 2028-08-01 · NCT06243393 · CT.gov ↗
What to watch
September 2028 (2)
Phase 1Advanced Solid TumorsRecruiting
Est. primary completion 2028-09 · NCT06167317 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2028-09-01 · NCT07947823 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2028-10 · NCT04230109 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-11-30 · NCT07393555 · CT.gov ↗
What to watch
December 2028 (1)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-12-30 · NCT06055465 · CT.gov ↗
What to watch
2029 (8)
February 2029 (1)
Phase 2Small Cell Lung Cancer ( SCLC ), Extensive Stage Small Cell Lung Cancer (ES-SCLC)Recruiting
Est. primary completion 2029-02-01 · NCT07339059 · CT.gov ↗
What to watch
April 2029 (1)
Phase 2Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma …Recruiting
Est. primary completion 2029-04-12 · NCT07504588 · CT.gov ↗
What to watch
June 2029 (2)
Phase 3Endometrial CancerActive not recruiting
Est. primary completion 2029-06 · NCT06486441 · CT.gov ↗
What to watch
Phase 2Mesothelioma, Mesotheliomas Pleural, Mesothelioma; PleuraRecruiting
Est. primary completion 2029-06-21 · NCT06477419 · CT.gov ↗
What to watch
September 2029 (2)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2029-09 · NCT05633667 · CT.gov ↗
What to watch
Phase 3Breast CancerRecruiting
Est. primary completion 2029-09 · NCT06081244 · CT.gov ↗
What to watch
October 2029 (2)
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2029-10 · NCT07151586 · CT.gov ↗
What to watch
Phase 3Extensive Stage Small Cell Lung Cancer (ES-SCLC)Recruiting
Est. primary completion 2029-10 · NCT06801834 · CT.gov ↗
What to watch
2030 (8)
January 2030 (1)
Phase 2Urothelial Bladder CarcinomaActive not recruiting
Est. primary completion 2030-01 · NCT06133517 · CT.gov ↗
What to watch
March 2030 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2030-03 · NCT05332561 · CT.gov ↗
What to watch
April 2030 (2)
Phase 2Salivary Gland Cancer, Thyroid CancerRecruiting
Est. primary completion 2030-04 · NCT06923826 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaActive not recruiting
Est. primary completion 2030-04 · NCT03547973 · CT.gov ↗
What to watch
September 2030 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-09-30 · NCT03424005 · CT.gov ↗
What to watch
December 2030 (3)
Phase 1/2Breast CancerRecruiting
Est. primary completion 2030-12 · NCT06963905 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2030-12-14 · NCT07271992 · CT.gov ↗
What to watch
Phase 3Urothelial CarcinomaRecruiting
Est. primary completion 2030-12-31 · NCT06524544 · CT.gov ↗
What to watch
2031 (2)
July 2031 (1)
Phase 1/2Endometrial CancerRecruiting
Est. primary completion 2031-07-01 · NCT06040970 · CT.gov ↗
What to watch
November 2031 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2031-11-30 · NCT06431633 · CT.gov ↗
What to watch
2033 (1)
March 2033 (1)
Phase 3Breast CancerNot yet recruiting
Est. primary completion 2033-03-31 · NCT07178730 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 June 2026Topline resultKEYNOTE-D46/EVOKE-03 (NCT05609968) Phase 3 discontinued: PFS primary endpoint not statistically significant
Merck and Gilead Sciences · Source ↗
October 2024WithdrawalGilead withdraws the US accelerated approval of Trodelvy in metastatic urothelial cancer
US, FDA · Gilead Sciences · Source ↗